Drug
Genvoya Dose
Genvoya Dose: highest development phase Post-Market, developed by Gilead Sciences. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Gilead Sciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| Genvoya Oral dose NCT03717129 | Post-Market | Healthy Volunteers |
Latest
No recent events.
Follow Genvoya Dose on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.